Condition: Cholangiocarcinoma · IDH Mutation · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
This description comes directly from the study's public registry record.
Thorsten Götze, Prof. Dr. · +49 69 76 01 · Goetze.Thorsten@KHNW.DE
Johanna Riedel, Dr. · +49 69 5899 787 · riedel.johanna@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Uniklinik RWTH Aachen | Aachen, Germany | Recruiting |
| Universitätsklinikum Bonn | Bonn, Germany | Recruiting |
| Uniklinikum Essen | Essen, Germany | Recruiting |
| Krankenhaus Nordwest | Frankfurt, Germany | Recruiting |
| Universitätsklinikum Frankfurt | Frankfurt, Germany | Recruiting |
| Universitätsklinik Gießen und Marburg GmbH Standort Gießen | Giessen, Germany | Recruiting |
| Universitätsmedizin Göttingen | Göttingen, Germany | Recruiting |
| Uniklinikum Jena | Jena, Germany | Recruiting |
| Universitätsmedizin Mainz | Mainz, Germany | Recruiting |
| Universitätsklinikum Mannheim | Mannheim, Germany | Recruiting |
| LMU Klinikum Großhadern | München, Germany | Recruiting |
| Klinikum rechts der Isar TU München | München, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07260175